Clinical trial
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
NCT00398450 · University of California, San Diego, Other · Completed
Key facts
| NCT number | NCT00398450 |
|---|---|
| Title | Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma |
| Official title | A Phase I Study of 5-azacytidine (Vidaza) With Interferon α2b in Metastatic Melanoma Patients |
| Lead sponsor | University of California, San Diego, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa-2b, azacitidine |
| Enrollment | 12 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Nov 10, 2006 |
| Last update posted | Mar 3, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: